CVS Health (CVS) Q1 earnings will beat estimates largely due to favorable medical loss ratio dynamics tied to the Inflation Reduction Act and Medicare Part D and a strong flu season, UBS Securities said in an earnings preview emailed on Tuesday.
The company's stock may not respond significantly unless there is greater clarity on Medical Advantage cost trends and membership mix, according to the preview.
The firm said that retail pharmacy might be protected due to dynamic maximum allowable cost pricing.
UBS said that the company faces regulatory risk if new legislation in Alaska that bans pharmacy benefit managers from owning pharmacies is adopted by other states.
The firm has a neutral rating on CVS stock with a $67 price target.
Price: 65.31, Change: +0.38, Percent Change: +0.59
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。